Table 1.
Baseline characteristics of the patients (n = 132).
| Characteristics | No. of patients (%) |
|---|---|
| Median age, years (range) | 51 (26–82) |
| Sex | |
| Male | 59 (44.7) |
| Female | 73 (55.3) |
| Histological type | |
| Adenocarcinoma | 116 (87.9) |
| Non-adenocarcinama | 16 (12.1) |
| Smoking history | |
| Never | 104 (78.8) |
| Current/former | 28 (21.2) |
| Stage at initiation of crizotinib | |
| IIIB | 10 (7.6) |
| IV | 109 (82.6) |
| Recurrent | 13 (9.8) |
| EGOG PS | |
| 0–1 | 122 (92.4) |
| ≥2 | 10 (7.6) |
| Distant metastases | |
| CNS | 40 (30.3) |
| Liver | 26 (19.7) |
| Bone | 47 (35.6) |
| Clinical type | |
| Central | 41 (31.1) |
| Peripheral | 91 (68.9) |
| Line of crizotinib treatment | |
| First | 95 (72.0) |
| ≥Second | 37 (28.0) |
Data are median values (range) or number of patients (%).
CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status.